{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:35:40Z","timestamp":1794512140294,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02962-8","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:04:02Z","timestamp":1762520642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Meir","family":"Schechter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Fishkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofri","family":"Mosenzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dvora R.","family":"Sehtman-Shachar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Cukierman-Yaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Leibowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genya","family":"Aharon-Hananel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"2","key":"2962_CR1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators","year":"2022","unstructured":"GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105\u201325. https:\/\/doi.org\/10.1016\/S2468-2667(21)00249-8.","journal-title":"Lancet Public Health"},{"key":"2962_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080952","volume":"388","author":"D Su","year":"2025","unstructured":"Su D, Cui Y, He C, et al. Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ. 2025;388:e080952. https:\/\/doi.org\/10.1136\/bmj-2024-080952.","journal-title":"BMJ"},{"issue":"3","key":"2962_CR3","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3233\/JAD-191092","volume":"73","author":"Q Cao","year":"2020","unstructured":"Cao Q, Tan C-C, Xu W, et al. The prevalence of dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2020;73(3):1157\u201366. https:\/\/doi.org\/10.3233\/JAD-191092.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2962_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13098-024-01346-4","volume":"16","author":"F Cao","year":"2024","unstructured":"Cao F, Yang F, Li J, et al. The relationship between diabetes and the dementia risk: a meta-analysis. Diabetol Metab Syndr. 2024;16(1):101. https:\/\/doi.org\/10.1186\/s13098-024-01346-4.","journal-title":"Diabetol Metab Syndr"},{"issue":"2","key":"2962_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/dom.15331","volume":"26","author":"A Kuate Defo","year":"2024","unstructured":"Kuate Defo A, Bakula V, Pisaturo A, Labos C, Wing SS, Daskalopoulou SS. Diabetes, antidiabetic medications and risk of dementia: a systematic umbrella review and meta-analysis. Diabetes Obes Metab. 2024;26(2):441\u201362. https:\/\/doi.org\/10.1111\/dom.15331.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2962_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","volume":"24","author":"DJ Drucker","year":"2025","unstructured":"Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025;24(8):631\u201350. https:\/\/doi.org\/10.1038\/s41573-025-01183-8.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"2962_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2962_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1007980","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang B, Wang R, et al. Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: an eight RCTs meta-analysis. Front Endocrinol (Lausanne). 2022;13:1007980. https:\/\/doi.org\/10.3389\/fendo.2022.1007980.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2962_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5853\/jos.2022.02306","volume":"25","author":"O Mosenzon","year":"2023","unstructured":"Mosenzon O, Cheng AY, Rabinstein AA, Sacco S. Diabetes and stroke: what are the connections? J Stroke. 2023;25(1):26\u201338. https:\/\/doi.org\/10.5853\/jos.2022.02306.","journal-title":"J Stroke"},{"issue":"3","key":"2962_CR10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/23969873241234238","volume":"9","author":"M-I Stefanou","year":"2024","unstructured":"Stefanou M-I, Theodorou A, Malhotra K, et al. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP\/GLP-1 receptor agonist tirzepatide for type 2 diabetes: a systematic review and meta-analysis. Eur Stroke J. 2024;9(3):530\u20139. https:\/\/doi.org\/10.1177\/23969873241234238.","journal-title":"Eur Stroke J"},{"issue":"2","key":"2962_CR11","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1161\/STROKEAHA.119.027557","volume":"51","author":"G Bellastella","year":"2020","unstructured":"Bellastella G, Maiorino MI, Longo M, et al. Glucagon-like peptide-1 receptor agonists and prevention of stroke systematic review of cardiovascular outcome trials with meta-analysis. Stroke. 2020;51(2):666\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.119.027557.","journal-title":"Stroke"},{"issue":"9","key":"2962_CR12","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm919","volume":"9","author":"MJ During","year":"2003","unstructured":"During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9(9):1173\u20139. https:\/\/doi.org\/10.1038\/nm919.","journal-title":"Nat Med"},{"key":"2962_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.970925","volume":"16","author":"N Reich","year":"2022","unstructured":"Reich N, H\u00f6lscher C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: an in-depth review. Front Neurosci. 2022;16:970925. https:\/\/doi.org\/10.3389\/fnins.2022.970925.","journal-title":"Front Neurosci"},{"issue":"5","key":"2962_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/jnr.10611","volume":"72","author":"T Perry","year":"2003","unstructured":"Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res. 2003;72(5):603\u201312. https:\/\/doi.org\/10.1002\/jnr.10611.","journal-title":"J Neurosci Res"},{"issue":"4","key":"2962_CR15","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3233\/JAD-143090","volume":"46","author":"HH Hansen","year":"2015","unstructured":"Hansen HH, Fabricius K, Barkholt P, et al. The GLP-1 receptor agonist Liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer\u2019s Disease. J Alzheimers Dis. 2015;46(4):877\u201388. https:\/\/doi.org\/10.3233\/JAD-143090.","journal-title":"J Alzheimers Dis"},{"key":"2962_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.peptides.2014.08.014","volume":"61","author":"R Lennox","year":"2014","unstructured":"Lennox R, Flatt PR, Gault VA. Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice. Peptides. 2014;61:38\u201347. https:\/\/doi.org\/10.1016\/j.peptides.2014.08.014.","journal-title":"Peptides"},{"key":"2962_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106550","volume":"186","author":"KO Kopp","year":"2022","unstructured":"Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment. Pharmacol Res. 2022;186:106550. https:\/\/doi.org\/10.1016\/j.phrs.2022.106550.","journal-title":"Pharmacol Res"},{"issue":"3","key":"2962_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.14336\/AD.2021.1029","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Liu C, Shi R, et al. Blocking C3d+\/GFAP+ A1 astrocyte conversion with semaglutide attenuates blood-brain barrier disruption in mice after ischemic stroke. Aging Dis. 2022;13(3):943\u201359. https:\/\/doi.org\/10.14336\/AD.2021.1029.","journal-title":"Aging Dis"},{"issue":"7","key":"2962_CR19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","volume":"24","author":"SP Yun","year":"2018","unstructured":"Yun SP, Kam T-I, Panicker N, et al. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease. Nat Med. 2018;24(7):931\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0051-5.","journal-title":"Nat Med"},{"issue":"7","key":"2962_CR20","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","volume":"19","author":"T Cukierman-Yaffe","year":"2020","unstructured":"Cukierman-Yaffe T, Gerstein HC, Colhoun HM, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 2020;19(7):582\u201390. https:\/\/doi.org\/10.1016\/S1474-4422(20)30173-3.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2962_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12268","volume":"8","author":"CH N\u00f8rgaard","year":"2022","unstructured":"N\u00f8rgaard CH, Friedrich S, Hansen CT, et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer\u2019s Demen Transl Res Clin Interv. 2022;8(1):e12268. https:\/\/doi.org\/10.1002\/trc2.12268.","journal-title":"Alzheimer's Demen Transl Res Clin Interv"},{"key":"2962_CR22","doi-asserted-by":"publisher","first-page":"153331751989954","DOI":"10.1177\/1533317519899546","volume":"35","author":"H Akimoto","year":"2020","unstructured":"Akimoto H, Negishi A, Oshima S, et al. Antidiabetic drugs for the risk of Alzheimer disease in patients with type 2 DM using FAERS. Am J Alzheimers Dis Other Demen. 2020;35:1533317519899546. https:\/\/doi.org\/10.1177\/1533317519899546.","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"10103","key":"2962_CR23","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(17)31585-4.","journal-title":"Lancet"},{"issue":"6","key":"2962_CR24","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson\u2019s disease. J Clin Investig. 2013;123(6):2730\u20136. https:\/\/doi.org\/10.1172\/JCI68295.","journal-title":"J Clin Investig"},{"issue":"13","key":"2962_CR25","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C, et al. Trial of lixisenatide in early Parkinson\u2019s disease. N Engl J Med. 2024;390(13):1176\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2312323.","journal-title":"N Engl J Med"},{"key":"2962_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2016.00108","volume":"8","author":"M Gejl","year":"2016","unstructured":"Gejl M, Gjedde A, Egefjord L, et al. In Alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci. 2016;8:108. https:\/\/doi.org\/10.3389\/fnagi.2016.00108.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"2962_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M, et al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024;23(1):37\u201345. https:\/\/doi.org\/10.1016\/S1474-4422(23)00378-2.","journal-title":"Lancet Neurol"},{"issue":"10479","key":"2962_CR28","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G, et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet. 2025;405(10479):627\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(24)02808-3.","journal-title":"Lancet"},{"issue":"5","key":"2962_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-19-0259","volume":"181","author":"IK Wium-Andersen","year":"2019","unstructured":"Wium-Andersen IK, Osler M, J\u00f8rgensen MB, Rungby J, Wium-Andersen MK. Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study. Eur J Endocrinol. 2019;181(5):499\u2013507. https:\/\/doi.org\/10.1530\/EJE-19-0259.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2962_CR30","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/brain\/awaa262","volume":"143","author":"R Brauer","year":"2020","unstructured":"Brauer R, Wei L, Ma T, et al. Diabetes medications and risk of Parkinson\u2019s disease: a cohort study of patients with diabetes. Brain. 2020;143(10):3067\u201376. https:\/\/doi.org\/10.1093\/brain\/awaa262.","journal-title":"Brain"},{"key":"2962_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.1189","author":"JA Luchsinger","year":"2025","unstructured":"Luchsinger JA, Rosin SP, Kazemi EJ, et al. Glucose-lowering medications, glycemia, and cognitive outcomes: the GRADE randomized clinical trial. JAMA Intern Med. 2025. https:\/\/doi.org\/10.1001\/jamainternmed.2025.1189.","journal-title":"JAMA Intern Med"},{"issue":"12","key":"2962_CR32","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","volume":"20","author":"W Wang","year":"2024","unstructured":"Wang W, Wang Q, Qi X, et al. Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024;20(12):8661\u201372. https:\/\/doi.org\/10.1002\/alz.14313.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2962_CR33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374. https:\/\/doi.org\/10.7326\/M16-2607.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2962_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"19","key":"2962_CR35","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"9","key":"2962_CR36","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1901118.","journal-title":"N Engl J Med"},{"issue":"3","key":"2962_CR37","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","volume":"31","author":"Y Xie","year":"2025","unstructured":"Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. 2025;31(3):951\u201362. https:\/\/doi.org\/10.1038\/s41591-024-03412-w.","journal-title":"Nat Med"},{"issue":"1","key":"2962_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40478-021-01180-z","volume":"9","author":"J-S Park","year":"2021","unstructured":"Park J-S, Kam T-I, Lee S, et al. Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer\u2019s disease. Acta Neuropathol Commun. 2021;9(1):78. https:\/\/doi.org\/10.1186\/s40478-021-01180-z.","journal-title":"Acta Neuropathol Commun"},{"key":"2962_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114187","volume":"180","author":"TS Salameh","year":"2020","unstructured":"Salameh TS, Rhea EM, Talbot K, Banks WA. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics. Biochem Pharmacol. 2020;180:114187. https:\/\/doi.org\/10.1016\/j.bcp.2020.114187.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"2962_CR40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s42255-025-01263-4","volume":"7","author":"A Vear","year":"2025","unstructured":"Vear A, Heneka MT, Clemmensen C. Incretin-based therapeutics for the treatment of neurodegenerative diseases. Nat Metab. 2025;7(4):679\u201396. https:\/\/doi.org\/10.1038\/s42255-025-01263-4.","journal-title":"Nat Metab"},{"key":"2962_CR41","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429","author":"S Gabery","year":"2020","unstructured":"Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020. https:\/\/doi.org\/10.1172\/jci.insight.133429.","journal-title":"JCI Insight"},{"issue":"2","key":"2962_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"24","key":"2962_CR43","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"1","key":"2962_CR44","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12933-022-01585-7","volume":"21","author":"O Mosenzon","year":"2022","unstructured":"Mosenzon O, Capehorn MS, De Remigis A, Rasmussen S, Weimers P, Rosenstock J. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials. Cardiovasc Diabetol. 2022;21(1):172. https:\/\/doi.org\/10.1186\/s12933-022-01585-7.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2962_CR45","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/brain\/awab015","volume":"144","author":"SH Jeong","year":"2021","unstructured":"Jeong SH, Chung SJ, Yoo HS, et al. Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson\u2019s disease. Brain. 2021;144(4):1127\u201337. https:\/\/doi.org\/10.1093\/brain\/awab015.","journal-title":"Brain"},{"issue":"1","key":"2962_CR46","doi-asserted-by":"publisher","first-page":"22489","DOI":"10.1038\/s41598-023-49870-z","volume":"13","author":"Y-H Lin","year":"2023","unstructured":"Lin Y-H, Hsu C-C, Liu J-S, Chang K-C, Huang J-A. Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson\u2019s disease in diabetic patients. Sci Rep. 2023;13(1):22489. https:\/\/doi.org\/10.1038\/s41598-023-49870-z.","journal-title":"Sci Rep"},{"key":"2962_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2020.100061","author":"BJ Peterson","year":"2020","unstructured":"Peterson BJ, Rocca WA, Bower JH, Savica R, Mielke MM. Identifying incident Parkinson\u2019s disease using administrative diagnostic codes: a validation study. Clin Parkinsonism Relat Disord. 2020. https:\/\/doi.org\/10.1016\/j.prdoa.2020.100061.","journal-title":"Clin Parkinsonism Relat Disord"},{"issue":"2","key":"2962_CR48","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/mds.30075","volume":"40","author":"SM Goldman","year":"2025","unstructured":"Goldman SM, Weaver FM, Cao L, et al. Validation of Parkinson\u2019s disease ascertainment in the veterans administration electronic medical record. Mov Disord. 2025;40(2):245\u201353. https:\/\/doi.org\/10.1002\/mds.30075.","journal-title":"Mov Disord"},{"key":"2962_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/alz.057848","author":"P Edison","year":"2021","unstructured":"Edison P, Femminella GD, Ritchie CW, et al. Evaluation of liraglutide in the treatment of Alzheimer\u2019s disease. Alzheimers Dement. 2021. https:\/\/doi.org\/10.1002\/alz.057848.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2962_CR50","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13063-019-3259-x","volume":"20","author":"GD Femminella","year":"2019","unstructured":"Femminella GD, Frangou E, Love SB, et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer\u2019s disease: study protocol for a randomised controlled trial (ELAD study). Trials. 2019;20(1):191. https:\/\/doi.org\/10.1186\/s13063-019-3259-x.","journal-title":"Trials"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02962-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02962-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02962-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:04:03Z","timestamp":1762520643000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02962-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2962"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02962-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS reports travel support from Novo Nordisk and AstraZeneca through Hadassah Medical Center, and lecturing fees from AstraZeneca (2022). AF and DRSS report no conflict of interest. OM reports Advisory Board membership for Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca and BOL Pharma, research grant support through Hadassah Hebrew University Hospital from Novo Nordisk and AstraZeneca, and Speaker's Bureau participation for AstraZeneca, Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, and Boehringer Ingelheim. From May 1st, 2023, OM has been an employee of Regeneron Pharmaceuticals\u00a0Inc. This work was not funded by Regeneron Pharmaceuticals, Inc.; it was not part of OM\u2019s job responsibilities; and the company had no role in conception, data acquisition, analysis, interpretation, or manuscript preparation. TCY reports receiving research support from Medtronic, Regeneron, Novo Nordisk, and Merck Sharp & Dohme. Honorarium for lecture\/advisory board from Medtronic, Sanofi, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, and Amgen. GL reports participation in previous Advisory Boards: Novo Nordisk, Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca and Medtronic. He reports travel support from Novo Nordisk, Boehringer Ingelheim and AstraZeneca through Hadassah Medical Center. Speaker's Bureau: AstraZeneca, Novo Nordisk, Eli Lilly, Boehringer\u00a0Ingelheim. GAH reported previous Advisory Board: Sanofi and Eli Lilly. She is a current PI in several RCTs conducted by Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca and Bayer including the CONFIDENCE study, through Hadassah Medical Center. GAH reports travel support from Novo Nordisk and Medetronic through Hadassah Medical Center and AstraZeneca through Sheba medical center. Speaker's Bureau: AstraZeneca, Novo Nordisk, Eli Lilly and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"426"}}